Edwards Lifesciences stock is currently in Phase 18 of its 18-phase Adhishthana cycle, hinting at a period of sluggish and range-bound price action until early 2027. This phase does not necessarily signal a bearish outlook, but the stock’s structure suggests limited upward momentum in the near future.
The Adhishthana Principles outline the stock’s journey through its Cakra formation, where a breakout typically occurs in Phase 9, leading to a significant upward movement. Edwards Lifesciences adhered closely to this pattern, experiencing a notable rally in Phase 9 and further momentum gains in Phase 10, defying the usual peak formation timing.
Despite defying the typical peak pattern, Edwards Lifesciences eventually reached its peak in Phase 11 before undergoing a decline, retracing most of its gains back to its Phase 9 breakout levels, aligning with the expectations outlined in the Adhishthana principles.
Following the completion of its Himalayan Formation, the stock entered the Guna Triads in Phase 14, which play a crucial role in determining whether a stock can attain Nirvana in Phase 18, the pinnacle of the cycle. However, Edwards Lifesciences lacked the necessary Satoguna, a sustained bullish structure, in its Guna Triads, indicating a slim possibility of achieving a Nirvana move in Phase 18.
Given the absence of Satoguna in the Guna Triads, it is unlikely that Edwards Lifesciences will experience a significant market move until the conclusion of Phase 18 in January 2027. While this doesn’t guarantee a bearish trend, the stock is expected to remain range-bound and choppy, presenting an opportunity for existing investors to consider utilizing range-bound spreads to benefit from the prolonged consolidation period.
Read more on benzinga.com